Comparative Pharmacology
Head-to-head clinical analysis: CARDENE SR versus CARDIZEM SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE SR versus CARDIZEM SR.
CARDENE SR vs CARDIZEM SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It produces relaxation of coronary vascular smooth muscle and dilation of coronary arteries, and also dilates peripheral arteries, reducing systemic vascular resistance and blood pressure.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes during depolarization, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
Initial: 30 mg orally twice daily (SR capsules). Titrate up to 60 mg twice daily. Usual maintenance: 30-60 mg twice daily.
Oral: Initial dose 60-120 mg twice daily; titrate to maximum 360 mg/day divided into two doses.
None Documented
None Documented
Terminal elimination half-life 8.6 hours (range 6-15 hours). Clinical context: No accumulation at steady state with TID dosing.
3.0-4.5 hours for diltiazem; metabolites (e.g., desacetyldiltiazem) up to 10 hours. Clinical context: dosing interval adjustment in hepatic impairment.
Renal: 60% (metabolites, unchanged drug <1%); Biliary/Fecal: 35%
Renal: 2-4% unchanged; hepatic metabolism: ~60-70% (including active metabolites); fecal: ~30-40%.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker